Galux provides molecular design technology to discover and develop novel drugs for incurable and rare diseases through its AI-based drug design platform. The company was founded in 2020 and has a strong foundation of advanced research and development capabilities, with a focus on identifying and developing novel therapeutics. Galux's drug design platform incorporates protein structure prediction, protein-protein interaction prediction, and protein-ligand interaction prediction technologies. The company has a track record of exceptional results, as evidenced by its performance in the CASP and CAPRI competitions. If you are interested in reaching out to Galux, you can contact them via email at [email protected].